MedPath

SIRTSEI PHARMACEUTICALS, INC.

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Phase 1
Recruiting
Conditions
Major Depressive Disorder
Depression
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-08-26
Last Posted Date
2025-10-29
Lead Sponsor
Sirtsei Pharmaceuticals, Inc.
Target Recruit Count
36
Registration Number
NCT06570369
Locations
πŸ‡ΊπŸ‡Έ

CenExel CNS, Garden Grove, California, United States

πŸ‡ΊπŸ‡Έ

Alivation Research, Lincoln, Nebraska, United States

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Phase 2
Recruiting
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2024-02-12
Last Posted Date
2025-11-03
Lead Sponsor
Sirtsei Pharmaceuticals, Inc.
Target Recruit Count
456
Registration Number
NCT06254612
Locations
πŸ‡ΊπŸ‡Έ

Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States

πŸ‡ΊπŸ‡Έ

Midwest Research Group, Saint Charles, Missouri, United States

πŸ‡ΊπŸ‡Έ

IMA Clinical Research, Albuquerque, New Mexico, United States

and more 42 locations

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2020-08-12
Last Posted Date
2022-04-25
Lead Sponsor
Sirtsei Pharmaceuticals, Inc.
Target Recruit Count
27
Registration Number
NCT04510298
Locations
πŸ‡ΊπŸ‡Έ

Collaborative Neuroscience Research, Garden Grove, California, United States

πŸ‡ΊπŸ‡Έ

Hassman Research Institute, Marlton, New Jersey, United States

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2020-07-21
Last Posted Date
2025-06-12
Lead Sponsor
Sirtsei Pharmaceuticals, Inc.
Target Recruit Count
319
Registration Number
NCT04479852
Locations
πŸ‡ΊπŸ‡Έ

Alea Research, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Woodland International Research Group, Little Rock, Arkansas, United States

πŸ‡ΊπŸ‡Έ

Woodland Research Northwest, Rogers, Arkansas, United States

and more 31 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.